22.418 articles found

Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists.

Shannon KM.

Nat Clin Pract Neurol · 2008-10-14

DOI: 10.1038/ncpneuro0934PMID: 18852725

METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE

UMBRICHT DANIEL, GOMEZ-MANCILLA BALTAZAR, GASPARINI FABRIZIO, DI PAOLO THERESE.

· 2008-10-09

Metabotropic glutamate receptor modulators for the treatment op Parkinson's Disease

GASPARINI FABRIZIO, GOMEZ-MANCILLA BALTAZAR, UMBRICHT DANIEL, PAOLO THERESE DI.

· 2008-10-09

Metabotropic glutamate receptor modulators for the treatment op parkinson's disease

FABRIZIO GASPARINI, BALTAZAR GOMEZ-MANCILLA, DANIEL UMBRICHT, DI PAOLO THERESE.

· 2008-10-09

Compounds, Compositions and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies

ESPOSITO LUKE A, HUDSON F. MICHAEL, LAKE THOMAS, CUMMINGS JOEL, WEIGELE MANFRED, SNOW ALAN, LARSEN LESLEY.

· 2008-10-03

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Jost WH, Klasser M, Reichmann H.

Fortschr Neurol Psychiatr · 2008-10-02

DOI: 10.1055/s-2008-1038249PMID: 18833504

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model.

Vanover KE, Betz AJ, Weber SM, Bibbiani F, Kielaite A, Weiner DM, Davis RE, Chase TN, Salamone JD.

Pharmacol Biochem Behav · 2008-10-01

DOI: 10.1016/j.pbb.2008.04.010PMID: 18534670

The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.

Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH.

Mov Disord · 2008-10-01

DOI: 10.1002/mds.22086PMID: 18759357

Supraventricular tachycardia-Part II: History, presentation, mechanism, and treatment.

Lee KW, Badhwar N, Scheinman MM.

Curr Probl Cardiol · 2008-10-01

DOI: 10.1016/j.cpcardiol.2008.06.004PMID: 18772055

Neuropathy as a potential complication of levodopa use in Parkinson's disease.

Toth C, Brown MS, Furtado S, Suchowersky O, Zochodne D.

Mov Disord · 2008-10-01

DOI: 10.1002/mds.22137PMID: 18785232

Exercise training acts as a therapeutic strategy for reduction of the pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model.

Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, Hwang DY, Cho JY.

Int J Mol Med · 2008-10-01

DOI: 10.3892/ijmm_00000052PMID: 18813861

Treatment of panic disorder with bupropion in a patient with Parkinson's disease.

Gebhardt S, Röttgers H, Bäcker A, Schu U, Krieg JC.

J Clin Pharm Ther · 2008-10-01

DOI: 10.1111/j.1365-2710.2008.00952.xPMID: 18834374